Zacks: Brokerages Expect Kindred Biosciences, Inc. (NASDAQ:KIN) Will Announce Earnings of -$0.22 Per Share


Share on StockTwits

Equities analysts predict that Kindred Biosciences, Inc. (NASDAQ:KIN) will announce earnings per share (EPS) of ($0.22) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Kindred Biosciences’ earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.29). Kindred Biosciences posted earnings of ($0.45) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 51.1%. The company is expected to report its next earnings report on Thursday, May 6th.

According to Zacks, analysts expect that Kindred Biosciences will report full-year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($0.87) to ($0.34). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.45) per share, with EPS estimates ranging from ($0.88) to $0.08. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last released its quarterly earnings data on Monday, March 15th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. The business had revenue of $0.95 million for the quarter, compared to analyst estimates of $0.96 million. Kindred Biosciences had a negative return on equity of 25.42% and a negative net margin of 62.50%.

Several equities analysts have recently weighed in on the company. Zacks Investment Research raised Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, March 9th. Alliance Global Partners reduced their price objective on Kindred Biosciences from $10.25 to $9.25 in a research note on Monday, December 21st. Finally, Aegis reaffirmed a “buy” rating on shares of Kindred Biosciences in a research note on Monday, February 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $9.95.

NASDAQ KIN opened at $4.92 on Monday. The firm has a market capitalization of $203.93 million, a P/E ratio of -7.13 and a beta of 1.19. Kindred Biosciences has a 1-year low of $3.20 and a 1-year high of $6.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 12.71 and a quick ratio of 12.64. The business’s 50-day simple moving average is $4.79 and its 200-day simple moving average is $4.48.

In other Kindred Biosciences news, major shareholder Park West Asset Management Llc sold 210,472 shares of Kindred Biosciences stock in a transaction that occurred on Thursday, January 28th. The stock was sold at an average price of $5.25, for a total transaction of $1,104,978.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Denise Bevers sold 8,396 shares of Kindred Biosciences stock in a transaction that occurred on Wednesday, March 17th. The stock was sold at an average price of $5.00, for a total value of $41,980.00. Following the sale, the director now owns 143,835 shares in the company, valued at $719,175. The disclosure for this sale can be found here. Insiders have sold a total of 231,891 shares of company stock worth $1,212,073 over the last three months. 12.63% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its holdings in shares of Kindred Biosciences by 4.2% in the 4th quarter. BlackRock Inc. now owns 2,672,113 shares of the biopharmaceutical company’s stock valued at $11,518,000 after acquiring an additional 108,527 shares during the last quarter. Ariel Investments LLC increased its holdings in shares of Kindred Biosciences by 14.4% in the 4th quarter. Ariel Investments LLC now owns 1,928,976 shares of the biopharmaceutical company’s stock valued at $8,314,000 after acquiring an additional 243,470 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Kindred Biosciences by 2.5% in the 4th quarter. Renaissance Technologies LLC now owns 1,589,859 shares of the biopharmaceutical company’s stock valued at $6,852,000 after acquiring an additional 38,161 shares during the last quarter. Silverback Asset Management LLC grew its stake in Kindred Biosciences by 1.6% during the 3rd quarter. Silverback Asset Management LLC now owns 590,545 shares of the biopharmaceutical company’s stock worth $2,533,000 after buying an additional 9,377 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in Kindred Biosciences by 20.3% during the 4th quarter. Wells Fargo & Company MN now owns 466,038 shares of the biopharmaceutical company’s stock worth $2,008,000 after buying an additional 78,643 shares during the last quarter. Institutional investors own 66.31% of the company’s stock.

About Kindred Biosciences

Kindred Biosciences, Inc, a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates.

See Also: Why is the ex-dividend date different from the record date?

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.